Betaserc



Indications and Reactions:

Role Indications Reactions
Primary
Anxiety 25.0%
Depression 25.0%
Product Used For Unknown Indication 25.0%
Vestibular Neuronitis 25.0%
Activities Of Daily Living Impaired 100.0%
Secondary
Drug Use For Unknown Indication 29.2%
Hypertension 13.2%
Vertigo 12.3%
Product Used For Unknown Indication 10.4%
Dementia 4.7%
Dizziness 3.8%
Dyslipidaemia 3.8%
Urinary Tract Infection 3.8%
Influenza Like Illness 2.8%
Dysuria 1.9%
Erysipelas 1.9%
Gastroduodenal Ulcer 1.9%
Influenza 1.9%
Sinusitis 1.9%
Unevaluable Event 1.9%
Anxiety 0.9%
Atrial Fibrillation 0.9%
Bronchopneumonia 0.9%
Depression 0.9%
Diabetes Mellitus 0.9%
Drug Rash With Eosinophilia And Systemic Symptoms 7.7%
Gingival Bleeding 7.7%
Hyperlactacidaemia 7.7%
Pancytopenia 7.7%
Toxic Skin Eruption 7.7%
White Blood Cell Count Increased 7.7%
Cerebral Haemorrhage 5.1%
Rash Papular 5.1%
Renal Failure Acute 5.1%
Sepsis 5.1%
Systemic Inflammatory Response Syndrome 5.1%
Tremor 5.1%
Weight Decreased 5.1%
Blood Alkaline Phosphatase Increased 2.6%
Cholestatic Liver Injury 2.6%
Gamma-glutamyltransferase Increased 2.6%
Hyponatraemia 2.6%
Melaena 2.6%
Orthostatic Hypotension 2.6%
Protein Total Increased 2.6%
Concomitant
Product Used For Unknown Indication 11.6%
Hypertension 11.1%
Drug Use For Unknown Indication 10.3%
Depression 8.2%
Vertigo 8.0%
Multiple Sclerosis 6.5%
Osteoporosis 5.6%
Diabetes Mellitus 4.2%
Dizziness 3.8%
Labyrinthitis 3.6%
Atrial Fibrillation 3.4%
Prophylaxis 3.4%
Breast Cancer 2.9%
Meniere's Disease 2.9%
Rheumatoid Arthritis 2.9%
Type 2 Diabetes Mellitus 2.7%
Anxiety 2.4%
Back Pain 2.2%
Hypothyroidism 2.2%
Myocardial Infarction 2.2%
Vomiting 22.7%
Visual Impairment 7.2%
Vertigo 6.2%
Fracture 5.2%
Hyponatraemia 5.2%
Pneumonia 5.2%
Diarrhoea 4.1%
Drug Ineffective 4.1%
Palpitations 4.1%
Rash 4.1%
Tooth Extraction 4.1%
Acute Myeloid Leukaemia 3.1%
Cerebrovascular Accident 3.1%
Epilepsy 3.1%
Gastric Polyps 3.1%
Lower Limb Fracture 3.1%
Multiple Sclerosis Relapse 3.1%
Nervous System Disorder 3.1%
Rash Macular 3.1%
Renal Failure 3.1%